NCT00958750已完成3 期
Investigator-initiated Single Blind, Two-armed, Randomized Phase 3 Clinical Trial to Compare Efficacy of 5% Minoxidil Topical Foam (5% Mtf) Once Daily Versus 2% Minoxidil Topical Solution (2% Mts) Twice Daily in Application on Females With Slightly to Moderate Androgenetic Alopecia Concerning Hair Volume
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 113
- 试验地点
- 1
- 主要终点
- Change of target area non-vellus hair count (TAHC) [n/cm²] after 24 weeks
研究概览
简要总结
The purpose of this study is to determine in women the risk/benefit profile and non-inferiority of a topical 5% Minoxidil foam formulation applied once daily for the treatment of androgenetic alopecia in comparison to 2% MTS used twice daily, using objective and subjective efficacy measures and safety assessments for a study period of 24 weeks.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Single (Investigator)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Female, age 18 or older, in general good health
- •Exhibits AGA based on a discernable decrease in hair density on the top of the scalp, relative to the sides and back of the scalp, with scalp hair density in involved area D3 to D6 on the Savin Density Scale (See Appendix 1)
- •Hair density equal or less than 220 hairs /cm2 measured with TrichoScan
- •Subjects who give their consent to the study after thoroughly clarification and who personally signed and dated the informed consent document indicating that the subject (or a legally acceptable representative), has been informed of all pertinent aspects of the trial
- •Women of childbearing potential, who practice an effective method of contraception for at least five consecutive weeks prior to the study entry and during the study with one of the following methods:
- •Double contraceptive method among hormonal contraception (e.g. contraceptive pill, intra uterine device, vaginal ring, injectable or implantable contraception), spermicide, condom and diaphragm. Oral/systemic contraception must have been the same during the past 6 months and will not be changed during the study
- •Sexual abstinence
- •Partner with a vasectomy (dated back more than 6 months) OR
- •Women of non-childbearing potential, i. e. postmenopausal (absence of menstrual bleeding for 2 years), or had hysterectomy, bilateral tubal ligation or bilateral ovariectomy
- •Women of childbearing potential must show a negative urine pregnancy test at Screening
- •Willing to maintain the same hairstyle, hair length and hair color throughout the study
- •Subjects who are willing and able to comply with scheduled visits, treatment plan, mini-tattoo, laboratory test and other trial procedures.
排除标准
- •Known to be hypersensitive to Minoxidil, hair dye (P-Phenylendiamin), Tattoo ink, propylene glycol, fragrances, hair gel or any vehicle components.
- •Current or 4 weeks dated back use of local treatment (drug or cosmetically) in the target region interfering with the study product or examination method (corticosteroids, Aminexil, Minoxidil, medical shampoos, topical estrogen, Ketoconazol)
- •Current or 3 months dated back use of systemic treatment (drugs or dietary supplement) taken for more than 2 consecutive weeks interfering with the study product or examination method (beta blocker, Cimetidine, Diazoxid, Isotretinoin, corticosteroids, vitamin A intake above 10000 IU per day)
- •Within past 6 month receiving of chemotherapy/cytotoxic agents as well as radiation and/or laser/surgical therapy of the scalp
- •Current or prior enrollment in any other investigational medication (drug) study within the last 4 weeks
- •Women with childbearing potential and insufficient contraception.
- •Female who is pregnant, planning a pregnancy (during the course of the study) or nursing a child
- •Presence of hair transplants, hair weaves or non-breathable wigs
- •Any dermatological disorders of the scalp in the target region with the possibility of interfering with the study product or examination method, such as fungal or bacterial infections, seborrheic dermatitis, psoriasis, eczema, folliculitis, scars or scalp atrophy
- •Active hair loss or history within the past 3 months including diffuse telogen effluvium, alopecia areata, scarring alopecia and androgen hair loss /hyper-androgenemia)
- •Other severe, acute or chronic medical condition that may lead to hair loss or interfere with the interpretation of trial results
- •Individuals who are institutionalized by court or regulatory order
研究组 & 干预措施
5% MTF
Active Comparator
5% minoxidil topical foam used once daily
干预措施: minoxidil (Drug)
2% MTS
Active Comparator
2% minoxidil topical solution twice daily use
干预措施: minoxidil (Drug)
结局指标
主要结局
Change of target area non-vellus hair count (TAHC) [n/cm²] after 24 weeks
时间窗: 24 weeks
次要结局
- Assessing the investigational products safety by means of clinical examination (local intolerance, facial hypertrichosis, AE, SAE) and blood Minoxidil level (baseline + week 24)(24 weeks)
- Change of cumulative hair width in non-vellus hair (TAHW) after 24 weeks(24 weeks)
- Global expert panel rating of change in scalp coverage via assessment of global photographs(24 weeks)
- Volunteer questionnaire rating for administration and contentment of the study product(24 weeks)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
不适用
A Comparative Clinical Study to Evaluate the Effectiveness of ProFlor vs. Lichtenstein for Inguinal Hernia RepairInguinal HerniaNCT02240550Insightra Medical, Inc.50
已完成
不适用
Safety and Performance of DKL Crosslinked Sodium Hyaluronate 23 Dermal Filler for Improvement of NLF AppearanceAging, PrematureNCT05021913Dr. Korman Laboratories Ltd.48
已完成
不适用
Double-Blind Study of Topical WBI-1001 Cream on Patients With PsoriasisPsoriasisNCT00830817Welichem Biotech Inc.36
已完成
3 期
MK0431A Comparative Study in Patients With Type 2 Diabetes (0431A-079)(COMPLETED)Type 2 Diabetes MellitusNCT00482729Merck Sharp & Dohme LLC1,246
已完成
不适用
Safety and Performance of DKL Crosslinked Sodium Hyaluronate 26 Dermal Filler for Cheek AugmentationAging ProblemsNCT05021926Dr. Korman Laboratories Ltd.48